ILMN: Leadership change

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately. Dr. Skovronsky will stand for election at the Company’s 2027 annual meeting of stockholders to serve for a one-year term commencing with such meeting. Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission. There is no arrangement or understanding between Dr. Skovronsky and any other person pursuant to which he was selected as a director. In addition, Dr. Skovronsky is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr. Skovronsky will participate in the non-employee director compensation programs described under “Director Compensation” in the Company’s proxy statement filed on April 9, 2026. A copy of the press release announcing the appointment of Dr. Skovronsky is attached as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Illumina, Inc. Press Release, dated June 23, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ILLUMINA, INC. Date: June 23, 2026 By: /s/ SCOTT DAVIES Name: Scott Davies Title: Chief Le